PL2666016T3 - Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej - Google Patents

Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej

Info

Publication number
PL2666016T3
PL2666016T3 PL12701341T PL12701341T PL2666016T3 PL 2666016 T3 PL2666016 T3 PL 2666016T3 PL 12701341 T PL12701341 T PL 12701341T PL 12701341 T PL12701341 T PL 12701341T PL 2666016 T3 PL2666016 T3 PL 2666016T3
Authority
PL
Poland
Prior art keywords
bubr1
biomarker
drug response
drug
response
Prior art date
Application number
PL12701341T
Other languages
English (en)
Inventor
Heidi Alexandra Lane
Felix Bachmann
Madlaina Breuleux
Michael Boutros
Daniel Gilbert
Xian Zhang
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of PL2666016T3 publication Critical patent/PL2666016T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
PL12701341T 2011-01-21 2012-01-19 Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej PL2666016T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11151677 2011-01-21
EP12701341.5A EP2666016B1 (en) 2011-01-21 2012-01-19 Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles

Publications (1)

Publication Number Publication Date
PL2666016T3 true PL2666016T3 (pl) 2017-07-31

Family

ID=43920866

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12701341T PL2666016T3 (pl) 2011-01-21 2012-01-19 Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej

Country Status (12)

Country Link
US (2) US10222377B2 (pl)
EP (1) EP2666016B1 (pl)
JP (1) JP6302673B2 (pl)
CN (1) CN103314295B (pl)
AU (1) AU2012208520B2 (pl)
CA (2) CA3142576A1 (pl)
DK (1) DK2666016T3 (pl)
ES (1) ES2620582T3 (pl)
HU (1) HUE032643T2 (pl)
PL (1) PL2666016T3 (pl)
PT (1) PT2666016T (pl)
WO (1) WO2012098207A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6334393B2 (ja) * 2011-03-29 2018-05-30 バジリア ファルマスーチカ アーゲーBasilea Pharmaceutica AG 薬物応答のバイオマーカーとしてのホスホAktの使用
WO2015173341A1 (en) * 2014-05-13 2015-11-19 Basilea Pharmaceutica Ag Dosage principle for anti-cancer furazanylbenzimidazoles
HK1257768A1 (zh) 2015-10-22 2019-10-25 Basilea Pharmaceutica International AG Eb1作为药物应答的生物标记物的用途
CA3058695A1 (en) 2017-04-26 2018-11-01 Basilea Pharmaceutica International AG Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
EP3624790A1 (en) 2017-05-16 2020-03-25 Basilea Pharmaceutica International AG Novel dosage principle for drugs useful for treating neoplastic diseases
CN107119137B (zh) * 2017-05-26 2018-04-06 广州华弘生物科技有限公司 一种快速检测HER‑2/neu基因表达的检测试剂盒
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7828698A (en) * 1997-06-11 1998-12-30 Chiron Corporation Detection of loss of the wild-type (hu)bub1 gene
US6593098B1 (en) 1997-12-01 2003-07-15 Fox Chase Cancer Center Genes encoding proteins involved in mitotic checkpoint control and methods of use thereof
CN100578227C (zh) * 2001-02-21 2010-01-06 诺华疫苗和诊断公司 用于诊断和作为癌症治疗靶标的ttk
WO2004058752A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
PT1636215E (pt) * 2003-05-23 2008-04-29 Basilea Pharmaceutica Ag Furazanobenzimidazoles
US20050136177A1 (en) * 2003-08-25 2005-06-23 Anthony Hesse Method for coloring landscaping materials using foamable dry colorant
US8021831B2 (en) * 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
JP5139811B2 (ja) * 2004-12-08 2013-02-06 アベンティス・ファーマスーティカルズ・インコーポレイテツド ドセタキセル耐性または感受性の測定方法
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Rsk1阻害作用を有する新規スピロインダン誘導体
BRPI0914649B1 (pt) * 2008-06-26 2021-07-06 Les Laboratoires Servier Pirazolo-quinazolinas
KR101758400B1 (ko) * 2009-07-27 2017-07-14 바실리어 파마슈티카 아게 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸

Also Published As

Publication number Publication date
JP6302673B2 (ja) 2018-03-28
HUE032643T2 (en) 2017-10-30
WO2012098207A1 (en) 2012-07-26
AU2012208520A1 (en) 2013-07-04
EP2666016A1 (en) 2013-11-27
EP2666016B1 (en) 2017-01-04
US9970938B2 (en) 2018-05-15
CA2822491C (en) 2023-02-14
HK1189056A1 (zh) 2014-05-23
US20160320397A1 (en) 2016-11-03
PT2666016T (pt) 2017-04-03
CN103314295A (zh) 2013-09-18
JP2014505877A (ja) 2014-03-06
ES2620582T3 (es) 2017-06-29
NZ611805A (en) 2015-05-29
AU2012208520B2 (en) 2016-03-10
CN103314295B (zh) 2016-03-16
DK2666016T3 (en) 2017-04-10
CA2822491A1 (en) 2012-07-26
US20140045897A1 (en) 2014-02-13
CA3142576A1 (en) 2012-07-26
US10222377B2 (en) 2019-03-05

Similar Documents

Publication Publication Date Title
SMT201600476B (it) Tenofovir alafenammide emifumarato
SMT201600308B (it) Composti di benzene arile-o eteroarile-sostituiti
DE112012003620T8 (de) Kartusche
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
EP2743656A4 (en) SPECTROSCOPE
EP2709645A4 (en) ENHANCED PEPTIDE PHARMACEUTICAL AGENTS
DE102011100082A8 (de) Traygreifvorrichtung
BR112014012016A2 (pt) compostos
CO6910197A2 (es) Compuestos novedosos
EP2765427A4 (en) Probe unit
FR2958287B1 (fr) Microreacteur
IL239447A0 (en) Novel compounds
EP2743655A4 (en) SPECTROSCOPE
BR112014000879A2 (pt) deflegmador
CO6960543A2 (es) 2-tiopirimidinonas
EP2671588A4 (en) Transdermal patch
DK3141251T3 (da) Koloskopi - forberedelse
BR112014009319A2 (pt) compostos farmacêuticos
CO6970601A2 (es) Nueva combinación
BR112014012043A2 (pt) emplastro
EP2654196A4 (en) CONVERTER
EP2775735A4 (en) ULTRASONIC SENSOR
BR112013022508A2 (pt) novos compostos de azaespirodecanona
FI20115271A7 (fi) Pohjallinen
DE112012000819A5 (de) Gurtbandfänger